Creatine Supplementation in Young Healthy Adults

September 17, 2024 updated by: Darren Candow, University of Regina

Effects of Equal-volume Creatine Supplementation With Different Dosing Strategies on Body Composition and Muscle Performance in Young Healthy Adults

The purpose is to compare the effects of bolus ingestion (5 grams) vs. intermittent ingestion (2 x 2.5 grams) of creatine supplementation vs. placebo for 21 days on measures of body composition (lean tissue mass-indicator of muscle mass, total body water) and muscle performance (i.e., power, strength, endurance).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Creatine is a naturally occurring compound produced in the liver and brain. Creatine can also be found in food products such as red meat and seafood or through commercially available manufactured creatine products (i.e. creatine supplementation).

Evidence-based research shows that creatine supplementation improves measures of body composition and muscle performance. However, the optimal creatine supplementation protocol to achieve these benefits is unknown.

Study Type

Interventional

Enrollment (Estimated)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Canada
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4S 0A2

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • if you are 18-39 years of age
  • if you have not been performing resistance training for at least 4 weeks prior to the start of the study.

Exclusion Criteria:

  • if you are pregnant or nursing
  • have taken creatine monohydrate within 30 days prior to the start of the study
  • if you have pre-existing allergies to the placebo (corn-starch maltodextrin)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Creatine Bolus
(Serving 1: 5 grams of creatine monohydrate + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.
Dietary supplement: Creatine
Creatine monohydrate
Experimental: Creatine Intermittent
(Serving 1: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the morning; Serving 2: 2.5 grams of creatine monohydrate + 5.5 grams of placebo in the evening) for 21 days.
Dietary supplement: Creatine
Creatine monohydrate
Placebo Comparator: Placebo
(Servings 1: 8 grams of placebo in the morning; Serving 2: 8 grams of placebo in the evening) for 21 days.
Dietary supplement: Placebo
Maltodextrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Whole-body lean mass (kg)
Time Frame: baseline, day 21
Bioelectrical impedance analysis
baseline, day 21
Strength
Time Frame: baseline, day 21
1-repetition maximum leg press and chest press (kg)
baseline, day 21
Endurance
Time Frame: baseline, day 21
Repetitions to fatigue for leg press and chest press (total number)
baseline, day 21
Hydration
Time Frame: baseline, day 21
Total body water (kg) using bioelectrical impedance analysis
baseline, day 21
Power
Time Frame: baseline, day 21
Vertical Jump (cm)
baseline, day 21
Power
Time Frame: baseline, day 21
Medicine Ball Throw (feet)
baseline, day 21

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Regina

Collaborators

Iovate Health Sciences International Inc

Investigators

  • Principal Investigator: Darren Candow, University of Regina

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 20, 2024

Primary Completion (Estimated)

January 31, 2025

Study Completion (Estimated)

January 31, 2025

Study Registration Dates

First Submitted

September 17, 2024

First Submitted That Met QC Criteria

September 17, 2024

First Posted (Actual)

September 20, 2024

Study Record Updates

Last Update Posted (Actual)

September 20, 2024

Last Update Submitted That Met QC Criteria

September 17, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 834

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe